Search results
PROMOTED
How do worsening heart events dictate the long-term outcomes of patients with transthyretin amyloid cardiomyopathy (ATTR-CM) and can earlier intervention influence the disease trajectory in ATTR-CM? In this new sub-analysis from ATTRibute-CM, recorded onsite at ESC Heart Failure Congress (HFA) 2026, Prof Marianna Fontana (University College London, London, UK) sheds further light onto these…
View more
HFA 2026: Updates on ATTR-CM
Added:
3 weeks ago
Video Series
Anticoagulation in Cardio-oncology
Added:
2 months ago
Review Article
Added:
9 months ago
ESC Congress 2025 - New guidelines for catheter-based VTE therapy emphasise the importance of involving vascular experts, and performing procedures in experienced centers.Dr Oliver Schlager (Medical University of Vienna, AT) joins us to discuss the newly released 2025 ESVM Guidelines on Interventional Treatment of Venous Thromboembolism, endorsed by European national societies of Vascular…
View more
Ibrutinib, Venetoclax and Adverse Cardiovascular Events
Added:
8 months ago
Expert Opinion
Added:
1 year ago
ESC HF 25 - Outcomes from a study investigating liver stiffness measurement as a non-invasive method to assess central venous pressure showed immediate results at bedside obtained in >4 minutes, with the procedure easily performed by a trained nurse.Prof Nicolas Girerd (University Hospital of Nancy, Nancy, FR) discusses a pilot validation study investigating liver stiffness as a non-invasive…
View more
Added:
1 month ago
Added:
1 month ago
Source:
Radcliffe CKM
Mirjam Boros, Radcliffe CardiologyA post hoc analysis of the SURPASS-CVOT trial suggests that tirzepatide, a dual GIP/GLP-1 receptor agonist, is associated with a lower incidence of a broad composite of cardiorenal events compared with the GLP-1 receptor agonist dulaglutide in patients with type 2 diabetes and established cardiovascular disease.¹Tirzepatide is a dual agonist that targets both…
View more
Could Acute COVID-19 Infection Ignite Thrombotic Risk?
Added:
1 year ago
Expert Opinion
Added:
2 months ago
Source:
Radcliffe CVRM
While glucagon-like peptide-1 receptor agonists (GLP-1RAs) have established cardiorenal benefits in type 2 diabetes, long-term data for their use in patients with type 1 diabetes (T1D) have been scarce. A new large-scale study suggests that initiating GLP-1RA therapy is associated with a lower risk of major adverse cardiovascular and kidney outcomes in this population, without compromising safety…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,…
View more